NEUROwave - Extracorporeal Shock Wave Therapy (ESWT) in Acute Traumatic Complete (AIS A) and Incomplete (AIS B-D) Cross-sectional Lesions on Motor and Sensory Function Within Six Months After Injury

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-99
SponsorAUVA

About this trial

It has been hypothesized that there are two mechanisms of acute traumatic spinal cord injury (SCI): the primary mechanical damage and the secondary injury due to additional pathological processes initiated by the primary injury. Neurological damage due to laceration, contusion, distraction or compression of the spinal cord is called ''primary injury''. This mechanical injury leads to a cascade of biochemical and pathological changes, described as ''secondary injury'', which occurs minutes to weeks after the initial trauma and causes further neurological deterioration. This secondary cascade involves vascular changes, an inflammatory response, neurotoxicity, apoptosis and glial scarring, and further compromises neurological impairment after traumatic spinal cord injury. Edema, ischemia and loss of autoregulation continue to spread bi-directionally from the initial lesion along the spinal cord for up to 72 hours after the trauma.

It has been postulated that the damage caused by the primary injury mechanism is irreversible and therapeutic approaches in recent years have focused on modulating the secondary injury cascade.

Researchers found significantly greater numbers of myelinated fibers in peripheral nerves after a single ESWT application in an experimental model on rats after a homotopic nerve autograft into the sciatic nerve.

In another study a spinal cord ischemia model in mice was performed. ESWT was applied immediately after surgery and the treated animals showed a significantly better motor function and decreased neuronal degeneration compared to the control group within the first 7 days after surgery.

Researchers investigated the effect of low-energy ESWT for the duration of three weeks on a thoracic spinal cord contusion injury model in rats. Animals in the ESWT group demonstrated significantly better locomotor improvement and reduced neuronal loss compared to the control animals at 7, 35, and 42 days after contusion.

It has been postulated previously, that ESWT improves the metabolic activity of various cell types and induces an improved rate of axonal regeneration.

ESWT might be a promising therapeutic strategy in the treatment of traumatic SCI.

The underlying study aims to investigate the effect of ESWT after acute traumatic spinal cord injury in humans within 48 hours of trauma in order to intervene in the secondary injury phase with the objective to reduce the extent of neuronal damage.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with acute traumatic spinal injuries who are awake, responsive, and oriented at admission

Patients from the age of 18 years

Admission to hospital within 24 hours after injury

Written consent to participate in the study

Disqualifiers

Patients who cannot cooperate or are not capable to give consent to participate

Serious traumatic brain injuries that prevent accurate participation in study procedures and/or adequacy of informed consent Participation in other interventional clinical trials

Serious concomitant injuries that prevent the neurological initial assessment

Preexisting neurological conditions that affect the primary endpoint of the study and potentially mask or reduce the therapeutic effect of the ESWT application

Trial design

Design model

Parallel

Treatments tested in this trial

  • Shock waves

    Device

    The shockwave generator orthogold 100® generates high-energy acoustic waves that behave much like other sound waves except that they have much greater pressure and energy. As with sound waves, Spark Waves® can easily travel great distance as long as the acoustic impedance stays the same.

  • dummy head

    Device

    The shockwave generator orthogold 100® will be used in combination with a dummy head, to Refrain shock waves

Treatment groups

246 Participants
are divided into 2 treatment groups
Group A: ESWTExperimental treatment 1 intervention
Group B: ControlSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

changes in total motor scores (TMSC) = TMSC after 6 month minus TMSC at baseline

greater improvement in motor and sensory function (the AIS grade) can be achieved in patients after spinal trauma (AIS A-D) by applying a single extracorporeal shockwave therapy compared to the control group.

Time frame
day 0 to 6 month

Secondary outcomes

1

American Spinal Injury Association (ASIA) Impaiment Scale (AIS) grade

the AIS grade ranges from AIS A to AIS D, whereby AIS A are complete lesions and AIS B-D represent incomplete lesions

Time frame
day 0 to 6 month
2

degree of spasticity

self-rated degree of spasticity according to Penn Spasm Frequency Scale (PSFS); the scale ranges from 0 to 4, whereby 0 refers to no spasticity and 4 refers to more than 10 spasms per hour

Time frame
day 0 to 6 month
3

Walking ability (yes/no)

walking ability is being assessed using different walking tests as part of standard clinical routine: Walking Index for Spinal Cord Injury (WISCI) II, Timed up and go test (TUG), 10 Meter-Timed-Walk, 6 Minute-Walk-Test

Time frame
day 0 to 6 month
4

Urological function

Urological function will be assessed by several questions which should be answered with yes or no: * Permanent catheter: yes/no * Sensation of urinary bladder filling: yes/no * Documentation of the first attempt of bladder emptying: pos/neg, date * Self-catheterization: yes/no * Do you feel sensory innervation of the external genitalia (penis / labia)? * Do you feel the change of the catheter or manipulations on the catheter? * Do you feel the urge to defecate? * Do you feel stool evacuation? * Male patients: Have you had an erection since your injury? * Female patients: Have you felt sexually aroused since your injury?

Time frame
day 0 to 6 month

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.